Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics

Journal of Thoracic and Cardiovascular Surgery

Volumn 139, Issue 3, 2010, Pages 646-654

  Toole, John M ^a,b   Ikonomidis, John S ^a,b   Szeto, Wilson Y ^c   Zellner, James L ^d   Mulcahy, John ^a,b   Deardorff, Rachael L ^a,b   Spinale, Francis G ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TENNESSEE AT CHATTANOOGA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; GLYCERYL TRINITRATE; HEPARIN; SITAXSENTAN; SODIUM CHLORIDE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HEART VALVE REPLACEMENT; HEMODYNAMICS; HUMAN; HYPERTENSION; LUNG RESISTANCE; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE;

AGED; CARDIOPULMONARY BYPASS; FEMALE; HEMODYNAMICS; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; RECEPTOR, ENDOTHELIN A; RISK FACTORS; SINGLE-BLIND METHOD; THIOPHENES; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 76749137130     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2009.11.046     Document Type: Article

References (37)

1. Krum H., and Liew D. Current status of endothelin-1 blockade for the treatment of cardiovascular and pulmonary vascular disease. Curr Opin Investig Drugs 4 (2003) 298-302
2. Miyauchi T., and Masaki T. Pathophysiology of endothelin-1 in the cardiovascular system. Annu Rev Physiol 61 (1999) 391-415
3. Bond B.R., Dorman B.H., Clair M.J., Walker C.A., Pinosky M.L., Reeves S.T., et al. Endothelin-1-1 during and after cardiopulmonary bypass: association to graft sensitivity and postoperative recovery. J Thorac Cardiovasc Surg 122 (2001) 358-364
4. Ivey M.E., Osman N., and Little P.J. Endothelin-1-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 199 (2008) 237-247
5. Pollock J.S., and Pollock D.M. Endothelin-1 and NOS1/nitric oxide signaling and regulation of sodium homeostasis. Curr Opin Nephrol Hypertens 17 (2008) 70-75
6. Mohácsi A., Magyar J., Tamás B., and Nánási P.P. Effects of endothelin-1s on cardiac and vascular cells: new therapeutic target for the future?. Curr Vasc Pharmacol 2 (2004) 53-63
7. D'Orléans-Juste P., Labonté J., Bkaily G., Choufani S., Plante M., and Honoré J.C. Function of the endothelin-1(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 95 (2002) 221-238
8. Giannessi D., Del Ry S., and Vitale R.L. The role of endothelin-1s and their receptors in heart failure. Pharmacol Res 43 (2001) 111-126
9. Ikonomidis J.S., Rao V., Weisel R.D., Hayashida N., and Shirai T. Myocardial protection for coronary bypass grafting: the Toronto Hospital perspective. Ann Thorac Surg 60 (1995) 824-832
10. Phillips H.R., Carter J.E., Okada R.D., Levine F.H., Boucher C.A., Osbakken M., et al. Serial changes in left ventricular ejection fraction in the early hours after aortocoronary bypass grafting. Chest 83 (1983) 28-34
11. Svircevic V., Nierich A.P., and Moons K.G. Brandon Bravo Bruinsma GJ, Kalkman CJ, van Dijk D. Fast-track anesthesia and cardiac surgery: a retrospective cohort study of 7989 patients. Anesth Analg 108 (2009) 727-733
12. Zingone B., Gatti G., Rauber E., Tiziani P., Dreas L., Pappalardo A., et al. Early and late outcomes of cardiac surgery in octogenarians. Ann Thorac Surg 87 (2009) 71-78
13. Mehta R.H., Hafley G.E., Gibson C.M., Harrington R.A., Peterson E.D., Mack M.J., et al. Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT)-IV Investigators. Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 136 (2008) 1149-1155
14. Woods S.E., Eppley C., and Engel A. The influence of diabetes mellitus in patients undergoing coronary artery bypass graft surgery: a prospective cohort study. Am Surg 74 (2008) 839-844
15. Scrutinio D., and Giannuzzi P. Comorbidity in patients undergoing coronary artery bypass graft surgery: impact on outcome and implications for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil 15 (2008) 379-385
16. Opitz C.F., Ewert R., Kirch W., and Pittrow D. Inhibition of endothelin-1 receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?. Eur Heart J 29 (2008) 1936-1948
17. Kirkby N.S., Hadoke P.W., Bagnall A.J., and Webb D.J. The endothelin-1 system as a therapeutic target in cardiovascular disease: great expectations or bleak house?. Br J Pharmacol 153 (2008) 1105-1119
18. Dhaun N., Pollock D.M., Goddard J., and Webb D.J. Selective and mixed endothelin-1 receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 28 (2007) 573-579
19. Kalra P.R., Moon J.C., and Coats A.J. Do results of the ENABLE (Endothelin-1 Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin-1 antagonism in heart failure?. Int J Cardiol 85 (2002) 195-197
20. Dorman B.H., New R.B., Bond B.R., Mukherjee R., Mukhin Y.V., McElmurray J.H., et al. Myocyte endothelin-1 exposure during cardioplegic arrest exacerbates contractile dysfunction after reperfusion. Anesth Analg 90 (2000) 1080-1085
21. Dupuis J., Goresky C.A., and Fournier A. Pulmonary clearance of circulating endothelin-1-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 81 (1996) 1510-1515
22. Barst R.J., Langleben D., Badesch D., Frost A., Lawrence E.C., Shapiro S., et al. STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-1-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
23. Benza R.L., Barst R.J., Galie N., Frost A., Girgis R.E., Highland K.B., et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 134 (2008) 775-782
24. Ford R.L., Mains I.M., Hilton E.J., Reeves S.T., Stroud R.E., Crawford Jr. F.A., et al. Endothelin-1-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation. Ann Thorac Surg 86 (2008) 1576-1583
25. Ikonomidis J.S., Hilton E.J., Payne K., Harrell A., Finklea L., Clark L., et al. Selective endothelin-1-A receptor inhibition after cardiac surgery: a safety and feasibility study. Ann Thorac Surg 83 (2007) 2153-2161
26. Wu C., Decker E.R., Biok N., Bui H., You T.J., Wang J., et al. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4-6-dimethylphenyl)-3-(3,4-dimethylisoxazaol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin-1 antagonist. J Med Chem 47 (2004) 1969-1986
27. Goldberg A.T., Bond B.R., Mukherjee R., New R.B., Zellner J.L., Crawford Jr. F.A., et al. Endothelin-1 receptor pathway in human left ventricular myocytes: relation to contractility. Ann Thorac Surg 69 (2000) 711-716
28. Thomas P.B., Liu E.C., Webb M.L., Mukherjee R., Hebbar L., and Spinale F.G. Exogenous effects and endogenous production of endothelin-1 in cardiac myocytes: potential significance in heart failure. Am J Physiol 271 6 Pt 2 (1996) H2629-H2637
29. Souza H.C., Terzini G.C., da Silva V.J., Martins-Pinge M.C., Salgado H.C., and Salgado M.C. Increased cardiac sympathetic drive and reduced vagal modulation following endothelin-1 receptor antagonism in healthy conscious rats. Clin Exp Pharmacol Physiol 35 (2008) 751-756
30. Ono K., Masumiya H., Sakamoto A., Christé G., Shijuku T., Tanaka H., et al. Electrophysiological analysis of the negative chronotropic effect of endothelin-1-1 in rabbit sinoatrial node cells. J Physiol 537 Pt 2 (2001) 467-488
31. Beaulieu P., and Lambert C. Peptidic regulation of heart rate and interactions with the autonomic nervous system. Cardiovasc Res 37 (1998) 578-585
32. Johnström P., Fryer T.D., Richards H.K., Harris N.G., Barret O., Clark J.C., et al. Positron emission tomography using 18F-labelled endothelin-1-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br J Pharmacol 144 (2005) 115-122
33. Ergul A., Grubbs A.L., Zhang Y., Joffs C., Sample J.A., King M.K., et al. Expression and activity of pulmonary endothelin-1 converting enzyme in heart failure: relation to endothelin-1 biosynthesis and receptor distribution. J Card Fail 7 (2001) 84-91
34. Multani M.M., Ikonomidis J.S., Kim P.Y., Miller E.A., Payne K.J., Mukherjee R., et al. Dynamic and differential changes in myocardial and plasma endothelin-1 in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 129 (2005) 584-590
35. Joffs C., Walker C.A., Hendrick J.W., Fary D.J., Almany D.K., Davis J.N., et al. Endothelin-1 receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass. J Thorac Cardiovasc Surg 122 (2001) 365-370
36. Yadav H., Unsworth B., Fontana M., Diller G.P., Kyriacou A., Baruah R., et al. Selective right ventricular impairment following coronary artery bypass graft surgery. Eur J Cardiothorac Surg (2009 Sep 14) [Epub ahead of print]
37. Haddad F., Couture P., Tousignant C., and Denault A.Y. The right ventricle in cardiac surgery, a perioperative perspective: II. Pathophysiology, clinical importance, and management. Anesth Analg 108 (2009) 422-433